Our study shows evidence supporting the hypothesis that for-profit-financed RCTs are associated with a higher OR for a favorable outcome of a new treatment than nonprofit- and mixed-funded RCTs, and that this difference is associated mainly with the use of surrogate endpoints in for-profit-financed drug trials.
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}